Roughly 910 patients will eventually decide whether blocking IL-6 alongside VEGF is the right idea in diabetic macular edema, and Kodiak Sciences just enrolled the first of them into the Phase 3 ALTO trial. The number matters because the study is not designed to show non-inferiority to aflibercept. It is powered for superiority, a design choice that sets a high evidentiary standard and signals genuine confidence in the Phase 2 data underpinning the program.
The biological rationale has been building for a while. Elevated intraocular IL-6 correlates with worse visual outcomes in patients receiving anti-VEGF monotherapy, which implies that vascular suppression alone leaves an inflammatory disease partially untreated. Kodiak’s Phase 2 ALLUVIUM study showed IL-6 inhibition alone produced clinically meaningful anatomic and functional gains in DME, and the Phase 2 BARDENAS study suggested that combining VEGF and IL-6 blockade produced synergistic effects beyond either pathway in isolation. ALTO is built to test whether that synergy holds in a registrational population, with a primary endpoint averaging best-corrected visual acuity change at Weeks 48 and 52, and a key secondary endpoint capturing two-step or greater improvement on the Diabetic Retinopathy Severity Scale at Week 48. That DRSS endpoint is not decorative: a meaningful shift there would indicate structural disease modification, not just fluid reduction.
The study also evaluates durability in a direct, testable way. One arm extends individualized dosing intervals to every 24 weeks, a six-month window built on the 20-day intraocular half-life of Kodiak’s ABC biopolymer conjugate platform. This runs alongside the more intensive every-eight-week arm, so ALTO will generate comparative durability data within the same trial. That is a different commitment than studying extended dosing in a separate open-label follow-on. Kodiak is already carrying the weight of one Phase 3 program: the DAYBREAK study in wet AMD completed enrollment at approximately 690 subjects, with topline data expected in September 2026. ALTO’s enrollment start makes this a two-front Phase 3 operation for a company that remains precommercial.
The specific number to track as ALTO enrolls is the proportion of patients in the six-month dosing arm who require interval compression before Week 96. If that proportion stays low while visual acuity outcomes hold, Kodiak’s durability argument becomes a concrete commercial differentiator rather than a platform-slide claim. DAYBREAK results in September will provide the first real read on whether the ABC platform performs in a registrational setting.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
